Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2001 1
2002 2
2004 1
2005 1
2006 4
2007 2
2009 2
2010 6
2011 2
2012 4
2013 8
2014 4
2015 3
2016 3
2017 4
2018 3
2019 4
2020 4
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean thomas g schell[Author] (3 results)?
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Jayne DRW, et al. Among authors: schall tj. N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386. N Engl J Med. 2021. PMID: 33596356 Clinical Trial.
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group. Jayne DRW, et al. Among authors: schall tj. J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11. J Am Soc Nephrol. 2017. PMID: 28400446 Free PMC article. Clinical Trial.
C5a receptor (CD88) blockade protects against MPO-ANCA GN.
Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC. Xiao H, et al. Among authors: schall tj. J Am Soc Nephrol. 2014 Feb;25(2):225-31. doi: 10.1681/ASN.2013020143. Epub 2013 Oct 31. J Am Soc Nephrol. 2014. PMID: 24179165 Free PMC article.
Cancer associated fibroblast FAK regulates malignant cell metabolism.
Demircioglu F, Wang J, Candido J, Costa ASH, Casado P, de Luxan Delgado B, Reynolds LE, Gomez-Escudero J, Newport E, Rajeeve V, Baker AM, Roy-Luzarraga M, Graham TA, Foster J, Wang Y, Campbell JJ, Singh R, Zhang P, Schall TJ, Balkwill FR, Sosabowski J, Cutillas PR, Frezza C, Sancho P, Hodivala-Dilke K. Demircioglu F, et al. Among authors: schall tj. Nat Commun. 2020 Mar 10;11(1):1290. doi: 10.1038/s41467-020-15104-3. Nat Commun. 2020. PMID: 32157087 Free PMC article.
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Merkel PA, Niles J, Jimenez R, Spiera RF, Rovin BH, Bomback A, Pagnoux C, Potarca A, Schall TJ, Bekker P; CLASSIC Investigators. Merkel PA, et al. Among authors: schall tj. ACR Open Rheumatol. 2020 Nov;2(11):662-671. doi: 10.1002/acr2.11185. Epub 2020 Oct 31. ACR Open Rheumatol. 2020. PMID: 33128347 Free PMC article.
Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells.
Wong PP, Muñoz-Félix JM, Hijazi M, Kim H, Robinson SD, De Luxán-Delgado B, Rodríguez-Hernández I, Maiques O, Meng YM, Meng Q, Bodrug N, Dukinfield MS, Reynolds LE, Elia G, Clear A, Harwood C, Wang Y, Campbell JJ, Singh R, Zhang P, Schall TJ, Matchett KP, Henderson NC, Szlosarek PW, Dreger SA, Smith S, Jones JL, Gribben JG, Cutillas PR, Meier P, Sanz-Moreno V, Hodivala-Dilke KM. Wong PP, et al. Among authors: schall tj. Cell. 2020 Jun 11;181(6):1346-1363.e21. doi: 10.1016/j.cell.2020.02.003. Epub 2020 May 29. Cell. 2020. PMID: 32473126 Free article.
Nonspecific CXCR7 antibodies.
Berahovich RD, Penfold ME, Schall TJ. Berahovich RD, et al. Among authors: schall tj. Immunol Lett. 2010 Oct 30;133(2):112-4. doi: 10.1016/j.imlet.2010.06.010. Epub 2010 Aug 6. Immunol Lett. 2010. PMID: 20691730 No abstract available.
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.
Sullivan KMC, Vilalta M, Ertl LS, Wang Y, Dunlap C, Ebsworth K, Zhao BN, Li S, Zeng Y, Miao Z, Fan P, Mali V, Lange C, McMurtrie D, Yang J, Lui R, Scamp R, Chhina V, Kumamoto A, Yau S, Dang T, Easterday A, Liu S, Miao S, Charo I, Schall TJ, Zhang P. Sullivan KMC, et al. Among authors: schall tj. PLoS One. 2023 Jun 7;18(6):e0286724. doi: 10.1371/journal.pone.0286724. eCollection 2023. PLoS One. 2023. PMID: 37285333 Free PMC article.
56 results